Plain-English translation of NCT06364176 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Cystic Fibrosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether , a blood pressure medication, can help improve how well your current cystic fibrosis treatment works. You're already taking elexacaftor/tezacaftor/ivacaftor (a combination therapy that helps fix the underlying CF problem), but some people still have signs that the disease is active. Researchers want to see if adding this medication to reduce inflammation might help your body respond even better to the treatment you're already on.
Even with newer CF therapies, some patients don't get the full benefit possible, and their sweat chloride levels (a marker of how well the CF protein is working) stay higher than ideal. This medication has anti-inflammatory properties that might help your body use your current CF therapy more effectively.
You likely qualify if…
You likely don't qualify if…
You would take the study medication twice daily for 12 weeks—starting with a lower dose for the first week, then increasing to the full dose for the remaining 11 weeks. Half of participants will receive the actual medication, and half will receive a placebo (inactive pill), and neither you nor the researchers will know which one you're getting during the study. The trial will track how your sweat chloride levels change and assess how your lungs are functioning over this period.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States